- Press releasesPress releases
- Events & ActivityEvents & Activity
- Veracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMA
- Veracyte Launches Campaign to Save Lives through Early Screening for Lung Cancer
- Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference
- Veracyte to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
- Veracyte Announces Second Quarter 2017 Financial Results
- Veracyte Announces Pivotal Clinical Validation Data for Afirma Genomic Sequencing Classifier Presented at World Congress on Thyroid Cancer
- Veracyte Announces Positive Data From Three Afirma Studies to Be Presented at World Congress on Thyroid Cancer
- Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on Monday, July 31, 2017
Veracyte Inc (VCYT:NMQ) closed at 8.61, -11.32% below its 52-week high of 9.71, set on Mar 29, 2017.
5.82Nov 02 20169.71Mar 29 2017
Markit short selling activity
|Market cap||287.76m USD|
|EPS (TTM)||-0.7991 |
Data delayed at least 15 minutes, as of Sep 26 2017 20:53 BST.